Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Breuer

Showing results (241-250 of 256) with videos related to

Pageof 26
Sort By:
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|July 17, 2021
Benchmark of thirteen bioinformatic pipelines for metagenomic virus diagnostics using datasets from clinical samplesJutte J C de Vries, Julianne R Brown, Nicole Fischer, et al.
The Lancet. Infectious Diseases|August 10, 2020
STROBE-metagenomics: a STROBE extension statement to guide the reporting of metagenomics studiesTehmina Bharucha, Clarissa Oeser, Francois Balloux, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2020
Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activitySuzanne J F Kaptein, Sofie Jacobs, Lana Langendries, et al.
BMJ Open Respiratory Research|September 21, 2021
SARS-CoV-2 lineage B.1.1.7 is associated with greater disease severity among hospitalised women but not men: multicentre cohort studyOliver Stirrup, Florencia Boshier, Cristina Venturini, et al.
Nature Microbiology|April 15, 2024
Age-specific nasal epithelial responses to SARS-CoV-2 infectionMaximillian N J Woodall, Ana-Maria Cujba, Kaylee B Worlock, et al.
Nature Microbiology|June 18, 2024
Author Correction: Age-specific nasal epithelial responses to SARS-CoV-2 infectionMaximillian N J Woodall, Ana-Maria Cujba, Kaylee B Worlock, et al.
The Lancet. Infectious Diseases|September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trialVictoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
BMJ Open|August 7, 2023
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe diseaseOghenekome Gbinigie, Emma Ogburn, Julie Allen, et al.
The Journal of Infection|April 25, 2021
Genetic epidemiology of SARS-CoV-2 transmission in renal dialysis units - A high risk community-hospital interfaceKathy K Li, Y Mun Woo, Oliver Stirrup, et al.
Nature Communications|February 23, 2024
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatientsJoseph F Standing, Laura Buggiotti, Jose Afonso Guerra-Assuncao, et al.
Pageof 26

Showing results (241-250 of 256) with videos related to

Sort By:
Pageof 26
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|July 17, 2021
Benchmark of thirteen bioinformatic pipelines for metagenomic virus diagnostics using datasets from clinical samplesJutte J C de Vries, Julianne R Brown, Nicole Fischer, et al.
The Lancet. Infectious Diseases|August 10, 2020
STROBE-metagenomics: a STROBE extension statement to guide the reporting of metagenomics studiesTehmina Bharucha, Clarissa Oeser, Francois Balloux, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2020
Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activitySuzanne J F Kaptein, Sofie Jacobs, Lana Langendries, et al.
BMJ Open Respiratory Research|September 21, 2021
SARS-CoV-2 lineage B.1.1.7 is associated with greater disease severity among hospitalised women but not men: multicentre cohort studyOliver Stirrup, Florencia Boshier, Cristina Venturini, et al.
Nature Microbiology|April 15, 2024
Age-specific nasal epithelial responses to SARS-CoV-2 infectionMaximillian N J Woodall, Ana-Maria Cujba, Kaylee B Worlock, et al.
Nature Microbiology|June 18, 2024
Author Correction: Age-specific nasal epithelial responses to SARS-CoV-2 infectionMaximillian N J Woodall, Ana-Maria Cujba, Kaylee B Worlock, et al.
The Lancet. Infectious Diseases|September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trialVictoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
BMJ Open|August 7, 2023
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe diseaseOghenekome Gbinigie, Emma Ogburn, Julie Allen, et al.
The Journal of Infection|April 25, 2021
Genetic epidemiology of SARS-CoV-2 transmission in renal dialysis units - A high risk community-hospital interfaceKathy K Li, Y Mun Woo, Oliver Stirrup, et al.
Nature Communications|February 23, 2024
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatientsJoseph F Standing, Laura Buggiotti, Jose Afonso Guerra-Assuncao, et al.
Pageof 26